Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer ... neuroinflammation in Alzheimer's disease. The study also integrates drug databases ...

Diet, exercise, brain games, even using your non-dominant hand can help prevent the onset of Alzheimer's disease.

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...